From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

— Partnership Combines Sequence Design Expertise with End-to-End GMP Manufacturing to Streamline mRNA Development and Scale-up — BIOVECTRA, a part of Agilent Technologies Inc., and Revolution ...

Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

The market for mRNA vaccines has experienced a surge fueled by the global rollout of the COVID-19 vaccines, and the potential of mRNA technology in public health opens a new frontier in medical ...

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc.

CHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSINESS WIRE)--BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service ...

The emerging field of mRNA therapeutics is still young. This class of therapeutics is poised to have broad implications in the treatment of many indications in addition to infectious diseases such as ...

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA ...